|
California Oncology Weekly
"Where California Oncologists Go For Answers!"
A collaborative publication of the
Medical Oncology Association of Southern California, Inc.
and the
Association of Northern California Oncologists, Inc.
February 16, 2016
|
|
|
|
|
- Forthcoming CMA webinars:
* HIPAA Compliance: Key Risks All Physicians Should Know (February 24)
* CMS Physician Compare Website (February 23, 24, 25)
* Closing a Medical Practice (March 9)
Register at www.cmanet.org/events.
- Members of the Save Lives California coalition have recently surpassed 175,000 signatures to qualify for the tobacco tax initiative for the November 2016 ballot. The coalition still has a long way to go, which is why CMA is asking for everyone to continue sending their petitions in. Signed petitions should be mailed to CMA headquarters at 1201 J Street, Suite 200, Sacramento, CA 95814 immediately after signatures are collected. Please email CMA at publicaffairs@cmanet.org to learn how you can help collect signatures.
|
|
|
* MLN Connects Provider eNews
Announcements--EHR Incentive Programs: Clinical Decision Support Interventions; EHR Incentive Programs: New Tipsiest on Eligibility for Broadband Access Exclusions Events--Provider Enrollment Revalidation Call-Registration Now Open; Physician Compare Public Reporting Information Sessions Claims, Prices, and
Publications & Videos--Telehealth Services Fact Sheet-Revised; Reading a Professional Remittance Advice Booklet-Reminder; * Drug Screen, G0431-Widespread Service Specific Probe Review Notification * ASP Medicare Part B Drug Pricing Files and Revisions to Prior Quarterly Pricing Files-April 2016 CR9536 * MolDX: HLA-B 15:02 Genetic Testing Final LCD-Effective April 1, 2016 * MolDX: Molecular RBC Phenotyping Final LCD-Effective April 1, 2016 |
|
|
- On February 24, EWC (Every Woman Counts) will conduct a meeting with stakeholders in Sacramento. EWC meets with stakeholders twice per year. Staff will provide an update on EWC activities. Meeting materials will be emailed to stakeholders prior to the meeting and will be posted on the DHCS website. For more information about EWC, please visit the DHCS website.
|
|
|
- SAVE THE DATE!
The MOASC General Membership Meeting, Saturday, April 30, 2016, 7:30am to 3:00pm
Decoding Molecular Medicine's "nibs" and "mabs." How new molecular advances fit into your treatment pattern for lung, breast and skin cancer. Hyatt Regency Long Beach, hotel rooms will be provided at a discounted rate, if needed, please contact moasc@moasc.org.
- MOASC Members are needed for a brief interview with the Managing Editor of Oncology Business Management. Anthony Hagen is interested in talking with a MOASC Member about AB 219 and your efforts to see this oral payment cap measure passed. This is for an upcoming story in Oncology Business Management magazine, which reaches about 15,000 oncologist/hematologists in the U.S. The purpose is to write about the background to the law and also provide an update on how successful it has been in terms of payer support and patient ability to meet the copay level specified by the measure.
|
|
|
- ANCO is pleased to be a sponsor of the 16th Multidisciplinary Management of Cancers: A Case-based Approach which returns to the Silverado Resort and Spa, Napa, on March 18-20, 2016. The meeting is presented in collaboration by the Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and UCSF Helen Diller Family Comprehensive Cancer Center. This meeting is almost full so register now for your chance to attend. For more information and to register, please visit http://cme.stanford.edu/multicancers.
|
|
|
- USP published General Chapter 800, Hazardous Drugs--Handling in Healthcare Settings--on February 1.The extent to which accrediting organizations or state boards will adopt USP 800, if they do so at all, remains unclear. ASCO is analyzing the chapter in detail and more information on the impact for practicing oncologists is forthcoming.
- On February 12, 2016 the Office for Civil Rights (OCR) released a HIPAA concern and has responded with Fact Sheets to address confusion. The Privacy, Security, and Breach Notification Rules under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) were intended to support information sharing by providing assurance to the public that sensitive health data would be maintained securely and shared only for appropriate purposes or with express authorization of the individual. Although the regulations have been in effect for quite some time, health care providers frequently still question whether the sharing of health information, even for routine purposes like treatment or care coordination, is permissible under HIPAA. Confusion about the rules has been cited by many as a potential obstacle to interoperability of digital health information. To address this confusion, the U.S. Department of Health and Human Services (HHS) Office of the National Coordinator for Health IT (ONC) and the Office for Civil Rights (OCR) have worked collaboratively to develop a series of topical fact sheets on HIPAA Permitted Uses and Disclosures that provide examples of when PHI can be exchanged under HIPAA without first requiring a specific authorization from the patient, so long as other protections or conditions are met. Click Here for the Permitted Uses and Disclosures: Exchange for Health Care Operations Fact Sheet. Click Here for the Permitted Uses and Disclosures: Exchange for Treatment Fact Sheet.
|
|
|
- Qualifiers for ICD-10 Diagnosis Codes on Electronic Claims. As you submit electronic claims for services, remember that:
* Claims with ICD-10 diagnosis codes must use ICD-10 qualifiers; all claims for services on or after October 1, 2015, must use ICD-10.
* Claims with ICD-9 diagnosis codes must use ICD-9 qualifiers; only claims for services before October 1, 2015, can use ICD-9.
How to use ICD-10 Qualifiers?
* For ASC X12 837P 5010A1 claims, the HI01-1 field for the Code List Qualifier Code must contain the code "ABK" to indicate the principal ICD-10 diagnosis code being sent. When sending more than one diagnosis code, use the qualifier code "ABF" for the Code List Qualifier Code to indicate up to 11 additional ICD-10 diagnosis codes that are sent.
* For ASC X12 837I 5010A1 claims, the HI01-1 field for the Principal Diagnosis Code List Qualifier Code must contain the code "ABK" to indicate the principal ICD-10 diagnosis code being sent. When sending more than one diagnosis code, use the qualifier code "ABF" for each Other Diagnosis Code to indicate up to 24 additional ICD-10 diagnosis codes that are sent.
* For NCPDP D.0 claims, in the 492.WE field for the Diagnosis Code Qualifier, use the code "02" to indicate an ICD-10 diagnosis code is being sent.
ASH has conversion charges for the most common hematologic ICD-10 codes as well as a pocket guide for ICD-10 coding for benign hematologic diseases at http://www.hematology.org/Clinicians/Practice-Policy/2325.aspx. - CMS announced the 2015 PQRS data submission timeframes: *EHR Direct or Data Submission Vendor (QRDA I or III) - 1/1/16 - 2/29/16 *Qualified Clinical Data Registries (QCDRs) (QRDA III) - 1/1/16 - 2/29/16 Group Practice Reporting Option (GPRO) Web Interface - 1/18/16 - 3/11/16 Qualified Registries (Registry XML) - 1/1/16 - 3/31/16 QCDRs (QCDR XML) - 1/1/16 - 3/31/16 Submission ends at 5:00 p.m. Pacific Time on the end date listed. An Enterprise Identity Management (EIDM) account with the "Submitter Role" is required for these PQRS data submission methods. Please see the EIDM System Toolkit for additional information. Please know that maintenance is currently scheduled for the following timeframes: *2/26/2016 at 5:00 p.m. PT - 2/29/2016 at 3:00 a.m. PT 3/11/2016 at 5:00 p.m. PT - 3/14/2016 at 3:00 a.m. PT 3/16/2016 at 5:00 p.m. PT - 3/21/2016 at 3:00 a.m. PT The Physician and Other Health Care Professionals Quality Reporting Portal (Portal) may be unavailable during these times.
|
Affiliate Association News
- ASCO's Clinical Affairs Department has released a new annual survey, the 2016 Survey of Oncology Practice Operations (SOPA), which seeks feedback on practice management. The business and operations data reported in this survey, open now through February 17, will be used to prepare benchmarks and standards in practice management, and all participants will receive a copy of the survey report. Take the survey at www.asco.org/advocacy/asco's-clinical-affairs-department-opens-new-survey-practice-operations. - Capitol Hill Day 2016 will serve as the kick-off for the Association of Community Cancer Centers (ACCC) 42nd Annual Meeting, CANCERSCAPE, March 2-4, 2016, in Washington D.C., where the policy conversation will continue. Capitol Hill Day 2015 mobilized ACCC members from 23 states to advocate for a permanent fix to the sustainable growth rate (SGR), oral chemotherapy parity legislation, and elimination of the prompt pay discount. More than 80 congressional meetings helped to pass legislation and positively influence the future of community oncology. Capitol Hill Day 2016 is Wednesday, March 2. - MORE THAN JUST A MEETING - THIS CONFERENCE IS AN EVENT! The most comprehensive community oncology conference is back, bringing together clinicians, practice administrators, payers, and industry leaders for two days of learning and networking. April 14-15, 2016 at The Lowes Royal Pacific Resort, Orlando. More than 600 oncologists, oncology nurses, practice administrators, allied cancer team professionals, and payers together for two days of learning and networking. From bundled payments to MIPS to the CMMI Oncology Care Model, the Conference covers issues critical to practices in the coming year. Attend a special panel of national employers discussing how they are dealing with paying for cancer care. Registration is open for the Community Oncology Alliance's (COA) 2016 Community Oncology Conference. - ASCO has announced that immunotherapy was the top cancer advance of 2016. Recent breakthroughs in immunotherapy--along with almost 60 other important cancer research advances--are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's Annual Report on Progress Against Cancer available online at http://www.cancerprogress.net/cca/clinical-cancer-advances-2016. - The Community Oncology Alliance Administrator's Network has a great set of resources. Tools are available for E&M services, HR forms, and dozens of other office forms. The resources are free, but join the Administrator's Network for more information. The resources are at http://can.communityoncology.org/site/forms.htm. - The Medical Group Management Association (MGMA) has a one-page report to review and compare the performance of your major payers. The tool can be modified to meet the needs of any size or type of medical practice. The resource can be found on the MGMA website at www.mgma.com/practice-resources/tools/payer-evaluation-spreadsheet-for-any-type-of-medical-practice.
|
Industry News
- AMGEN is hosting a webinar series entitled 2016 Medicare Updates and covering the 2016 Medicare Physician Fee Schedule and Outpatient Prospective Payment System as they relate to AMGEN Oncology, as well as other coding and Medicare developments of relevance to practice managers. For more information, please contact your AMGEN representative. This webinar is part of The Amgen Assist® Learning Tree, which is designed to provide a variety of access and reimbursement information. This series will be offered on four separate dates, beginning the week of February 15, 2016. Details related to each of the webinars are outlined in the invitation. Medicare Webinar Invitation 2016- Merck informs MOASC and ANCO of another indication for EMEND. Please see the following information. Prescribing Information Patient Product Information. If you have any questions, please contact Mike Nicolucci, Account Manager, Reimbursement (C) 913 522-6508 (F) 215 616-5889 mike.nicolucci@merck.com - Novartis Oncology has announced NDC changes for former GlaxoSmithKline Products, as follows: Arzerra (1vial x 50mL), new NDC #0078-0690-61; Arzerra (3 vials x 5mL), new NDC #0078-066-13. - nanoString informs ANCO and MOASC that the update ASCO guideline on the use of tumor markers in early stage breast cancer includes an update that if a patient has ER/PgR-positive, HER2-negative (node-negative) breasts cancer, the clinician may use the PAM50 risk of recurrence (ROR) score (Prosigna Breast Cancer Prognostic Gene Signature Assay), in conjunction with other clinics-pathologic variables, to guide decisions on adjuvant systemic therapy. The guideline assigns evidence-based, high-quality evidence, and a strong recommendation to Prosigna.
|
|
|
-
MOASC CALENDAR
LunchTime Series Teleconference/Webinar
April 27th June 29th August 31st October 26th Oncology Roundtable Teleconference March 2nd May 25th July 27th September 28th November 30th
ASH Highlights in
San Diego, CA
January 29th - 30th
NCCN in Florida
April 1st - 2nd General Membership Meeting April 29-30
ASCO National Meeting
in Chicago, II
June 3rd - June 6th ASCO State Affiliate
Meeting in Virginia, VAOctober 26th - 28th MOASC Billers Program November 30th
| |
(March 18-20; Napa)
|
|
|
|
|
The Medical Oncology Association of Southern California(MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the California Oncology Weekly is intended as general information for ANCO and MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC or ANCO accepts no liability for any statements or articles herein.CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
MOASC: P.O. Box 161, Upland, CA 91785 | P (909) 985-9061 | F (909) 804-5006| www.moasc.org
ANCO: P.O. Box 151109, San Rafael, CA 94915 | P (415) 472-3960 | F (415) 472-3961 | www.anco-online.org |
|
|
|
|
